Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;75(6):1445-1453.
doi: 10.1007/s43440-023-00534-9. Epub 2023 Nov 3.

Therapeutic, diagnostic and prognostic values of TRIM proteins in prostate cancer

Xiaojiang Li  1 , Yuzhuo Bai  2 , Ke Feng  3 , Zhendong Chu  4 , Haijun Li  5 , Zhicheng Lin  6 , Lin Tian  7
Affiliations
Review

Therapeutic, diagnostic and prognostic values of TRIM proteins in prostate cancer

Xiaojiang Li et al. Pharmacol Rep. 2023 Dec.

Abstract

Prostate cancer is the second most prevalent cancer in men worldwide. The TRIM (tripartite motif) family of proteins is involved in the regulation of various cellular processes, including antiviral immunity, apoptosis, and cancer progression. In recent years, several TRIM proteins have been found to play important roles in prostate cancer initiation and progression. TRIM proteins have indicated oncogenic activity in prostate cancer by enhancing androgen or estrogen receptor signaling and promoting cancer cell growth. Inhibition of TRIM proteins has been raised as a potential therapeutic strategy for the treatment of prostate cancer. Overall, these studies suggest that TRIM family proteins exert tumor-promoting effects in prostate cancer, and targeting these proteins can provide a promising therapeutic strategy for prostate cancer treatment. On the other hand, some TRIM proteins can be differentially expressed in prostate cancer cells compared to normal cells, thus providing novel diagnostic/prognostic biomarkers for prostate cancer.

Keywords: Oncogenesis; Prostate cancer; TRIM proteins.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. - DOI - PubMed
    1. Ito K, Kimura T. Complex epidemiology of prostate cancer in Asian countries. J Urol Oncol. 2023;21:5–13.
    1. Berenguer CV, Pereira F, Câmara JS, Pereira JAM. Underlying features of prostate cancer—statistics, risk factors, and emerging methods for its diagnosis. Curr Oncol. 2023;30:2300–21. - PubMed - PMC
    1. Hjazi A. The effects of Capsicum annuum supplementation on lipid profiles in adults with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2023;37(9):3859–66. https://doi.org/10.1002/ptr.7922 . - DOI - PubMed
    1. Garg H, Dursun F, Alsayegh F, Wang H, Wu S, Liss MA, et al. Revisiting current national comprehensive cancer network (NCCN) high-risk prostate cancer stratification: a national cancer database analysis. Prostate Cancer Prostatic Dis. 2023. https://doi.org/10.1038/s41391-022-00621-7 . - DOI - PubMed

Substances

LinkOut - more resources